EXTON, Pa.--(BUSINESS WIRE)--Othera Pharmaceuticals, Inc. today announced the enrollment of the first patient in a Phase II clinical trial of Othera’s topical eye drop OT-551 in patients with Geographic Atrophy (GA), an advanced form of dry Age-Related Macular Degeneration (AMD). The study is being conducted at the NIH Medical Center in Bethesda, MD. The study is designed to evaluate OT-551’s potential to reduce the loss in central visual acuity and to slow enlargement of the atrophic area in the macula. OT-551 has high bioavailability in the eye and distributes to the retina after topical dosing.
